 "Cadila Healthcare gains 4% on USFDA nod for Metoprolol Succinate tablets")
Cadila Healthcare was trading 4.4% higher at Rs 386 on the BSE in otherwise subdued market after the company said that Zydus Cadila has received final approval from the US regulator for Metoprolol Succinate extended-release tablets.
“Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Metoprolol Succinate extended-release tablets USP in the strengths of 25mg, 50mg, 100mg and 200mg,” Cadila Healthcare said in a press release.
The drug is used to treat chest pain, heart failure and high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems. The drug will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad, it added.
The group has now more than 185 approvals and has so far filed over 320 ANDAs since the commencement of the filling process in FY 2003-24, the company said.
At 09:45 am; the stock was trading 4% higher at Rs 385 as compared to 0.01% rise in the S&P BSE Sensex. A combined around 700,000 shares changed hands on the counter on the BSE and NSE.
“Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Metoprolol Succinate extended-release tablets USP in the strengths of 25mg, 50mg, 100mg and 200mg,” Cadila Healthcare said in a press release.
The drug is used to treat chest pain, heart failure and high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems. The drug will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad, it added.
The group has now more than 185 approvals and has so far filed over 320 ANDAs since the commencement of the filling process in FY 2003-24, the company said.
At 09:45 am; the stock was trading 4% higher at Rs 385 as compared to 0.01% rise in the S&P BSE Sensex. A combined around 700,000 shares changed hands on the counter on the BSE and NSE.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%